Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 489
- Registration Number
- NCT00615602
- Locations
- 🇬🇷
University Hospital of Crete, Heraklion, Crete, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 55
- Registration Number
- NCT00574587
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT00567879
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸VA Maryland Health Care Dept.of GreenbaumCancerCent(3), Baltimore, Maryland, United States
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 808
- Registration Number
- NCT00567190
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸LAC USC Medical Center, Los Angeles, California, United States
🇺🇸St. Barnabas Cancer Center, Livingston, New Jersey, United States
Lapatinib and Trastuzumab With or Without Endocrine Therapy
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Baylor Breast Care Center
- Target Recruit Count
- 65
- Registration Number
- NCT00548184
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bunting-Blaustein Cancer Research, Baltimore, Maryland, United States
🇺🇸UAB Cancer Center, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Bevacizumab in Multiple Phase I Combinations
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 343
- Registration Number
- NCT00543504
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 406
- Registration Number
- NCT00542451
- Locations
- 🇺🇸
Case Western University, Cleveland, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
- Conditions
- Interventions
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT00524303
- Locations
- 🇺🇸
GSK Investigational Site, Yakima, Washington, United States
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 50
- Registration Number
- NCT00490646
- Locations
- 🇹🇷
Local Institution, Izmir, Turkey
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 529
- Registration Number
- NCT00486668
- Locations
- 🇺🇸
CCOP, William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸CCOP, Hematology-Oncology Associates of CNY, Syracuse, New York, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.